Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer.
Channing J PallerLin WangWei FuRajendra KumarJennifer N DurhamNilofer S AzadDaniel A LaheruIlene BrownerSushant K KachhapKavya BoyapatiThomas A OdenyDeborah K ArmstrongChristian F MeyerStephanie GaillardJulie R BrahmerIvelisse PageHao WangLuis A DiazPublished in: Cancer research communications (2023)
Although ME is widely used for cancers, its efficacy and safety are uncertain. This first phase I trial of intravenous mistletoe (Helixor M) aimed to determine phase II dosing and to evaluate safety. We recruited 21 patients with relapsed/refractory metastatic solid tumor. Intravenous mistletoe (600 mg, 3/week) demonstrated manageable toxicities (fatigue, nausea, and chills) with disease control and improved QoL. Future research can examine ME's effect on survival and chemotherapy tolerability.
Keyphrases
- phase ii
- open label
- clinical trial
- placebo controlled
- advanced cancer
- phase iii
- high dose
- palliative care
- double blind
- study protocol
- squamous cell carcinoma
- small cell lung cancer
- acute myeloid leukemia
- acute lymphoblastic leukemia
- diffuse large b cell lymphoma
- oxidative stress
- chemotherapy induced
- hodgkin lymphoma
- low dose
- radiation therapy
- multiple myeloma
- current status
- anti inflammatory
- free survival